

Medical drug benefit *Clinical Criteria* updates

On November 15, 2019, the Pharmacy and Therapeutics (P&T) Committee approved the following *Clinical Criteria* applicable to the **medical drug benefit** for Amerigroup Community Care. These policies were developed, revised or reviewed to support clinical coding edits.

Visit [Clinical Criteria](#) to search for specific policies. For questions or additional information, use this [email](#).

Please see the explanation/definition for each category of *Clinical Criteria* below:

- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Annual Review: minor wording and formatting updates, new document number
- Updates marked with an asterisk (*): criteria may be perceived as more restrictive

Please share this notice with other members of your practice and office staff.

Please note: The *Clinical Criteria* listed below applies only to the medical drug benefits contained within the member's medical plan. This does not apply to pharmacy services.

| Effective date | Document number | <i>Clinical Criteria</i> title | New, revised, annual review |
|----------------|-----------------|---|-----------------------------|
| March 17, 2020 | ING-CC-0148 | <i>Agents for Hemophilia B</i> | New |
| March 17, 2020 | ING-CC-0149* | <i>Select Clotting Agents for Bleeding Disorders</i> | New |
| March 17, 2020 | ING-CC-0150* | <i>Kymriah (tisagenlecleucel)</i> | Revised |
| March 17, 2020 | ING-CC-0151 | <i>Yescarta (axicabtagene ciloleucel)</i> | Revised |
| March 17, 2020 | ING-CC-0059 | <i>Selected Injectable NK-1 Antiemetic Agents</i> | Revised |
| March 17, 2020 | ING-CC-0056 | <i>Selected Injectable 5HT3 Antiemetic Agents</i> | Revised |
| March 17, 2020 | ING-CC-0074 | <i>Akynzeo (fosnetupitant and palonosetron) for injection</i> | Revised |
| March 17, 2020 | ING-CC-0065* | <i>Agents for Hemophilia A and von Willebrand Disease</i> | Revised |
| March 17, 2020 | ING-CC-0124 | <i>Keytruda (pembrolizumab)</i> | Revised |
| March 17, 2020 | ING-CC-0127 | <i>Darzalex (daratumumab)</i> | Revised |
| March 17, 2020 | ING-CC-0133 | <i>Aliqopa (copanlisib)</i> | Revised |
| March 17, 2020 | ING-CC-0128 | <i>Tecentriq (atezolizumab)</i> | Revised |
| March 17, 2020 | ING-CC-0002* | <i>Colony Stimulating Factor Agents</i> | Revised |
| March 17, 2020 | ING-CC-0041* | <i>Complement Inhibitors</i> | Revised |
| March 17, 2020 | ING-CC-0071* | <i>Entyvio (vedolizumab)</i> | Revised |
| March 17, 2020 | ING-CC-0064* | <i>Interleukin-1 Inhibitors</i> | Revised |

| Effective date | Document number | Clinical Criteria title | New, revised, annual review |
|-----------------------|------------------------|--|------------------------------------|
| March 17, 2020 | ING-CC-0042* | <i>Monoclonal Antibodies to Interleukin-17</i> | Revised |
| March 17, 2020 | ING-CC-0066* | <i>Monoclonal Antibodies to Interleukin-6</i> | Revised |
| March 17, 2020 | ING-CC-0050* | <i>Monoclonal Antibodies to Interleukin-23</i> | Revised |
| March 17, 2020 | ING-CC-0078* | <i>Orencia (abatacept)</i> | Revised |
| March 17, 2020 | ING-CC-0063* | <i>Stelara (ustekinumab)</i> | Revised |
| March 17, 2020 | ING-CC-0062* | <i>Tumor Necrosis Factor Antagonists</i> | Revised |
| March 17, 2020 | ING-CC-0003* | <i>Immunoglobulins</i> | Revised |
| March 17, 2020 | ING-CC-0039 | <i>GamaSTAN immune globulin (human)</i> | Revised |
| March 17, 2020 | ING-CC-0043* | <i>Monoclonal Antibodies to Interleukin-5</i> | Revised |
| March 17, 2020 | ING-CC-0055 | <i>Fuzeon (enfuvirtide)</i> | Revised |
| March 17, 2020 | ING-CC-0047 | <i>Trogarzo (ibalizumab-uiyk)</i> | Revised |
| March 17, 2020 | ING-CC-0053 | <i>Injectable Hydroxyprogesterone for Prevention of Preterm Birth</i> | Revised |
| March 17, 2020 | ING-CC-0073 | <i>Alpha-1 Proteinase Inhibitor Therapy</i> | Revised |
| March 17, 2020 | ING-CC-0049 | <i>Radicava (edaravone)</i> | Revised |
| March 17, 2020 | ING-CC-0040 | <i>Prialt (ziconotide)</i> | Revised |
| March 17, 2020 | ING-CC-0079 | <i>Strensiq (asfotase alfa)</i> | Revised |
| March 17, 2020 | ING-CC-0075 | <i>Rituximab Agents for Non-Oncologic Indications</i> | Revised |
| March 17, 2020 | ING-CC-0072* | <i>Selective Vascular Endothelial Growth Factor (VEGF) Antagonists</i> | Revised |
| March 17, 2020 | ING-CC-0035 | <i>Duopa (carbidopa and levodopa enteral suspension)</i> | Revised |